Biocon Limited has informed the Exchange about Transcript

Biocon delivered a resilient Q4 FY26 with 10% YoY operating revenue growth (excluding one-time generic lenalidomide benefit from prior year base). Biosimilars revenue was ₹2,756 crores (+12% YoY) with EBITDA margin expanding to 26%, driven by favorable revenue mix and operating leverage. Generics revenue of ₹847 crores grew 13% YoY adjusted for lenalidomide, with margins improving nearly 300 bps sequentially to 8%. The company completed integration of its biosimilars and generics business in under 100 days with no disruption. Key launches included US commercial launches of Bosaya™ and Aukelso™ (denosumab biosimilars) and FDA approval for liraglutide. The insulin franchise crossed $300M and adalimumab exceeded $250M. Management emphasized the major investment phase is substantially complete with focus now on driving operating leverage, expanding margins, and cash generation. Net debt reduced from $1.5B to $1.1B with interest cost savings of ₹75 crores per quarter beginning to accrue.